dry eye

Fluorometholone (Fluoromethalone) is a corticosteroid, most often used after laser-based refractive surgery. It is marketed under the brand names FML (Allergan) and Flarex (Alcon). Fluorometholone acetate ophthalmic suspension is indicated for use in the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the eye.

Lifitegrast (SAR 1118) is an antagonist of lymphocyte function-associated antigen-1.

JAK-IN-10 is a JAK inhibitor that can be used for the research of dry eye disorders.

Namirotene (CBS 211A) is a protein biosynthesis inhibitor, a synthetic retinoic acid analog that is used in the study of corneal diseases, corneal ulcers and dry eye syndrome.

Simpinicline (OC-02) (OC-02) is a highly selective nicotinic acetylcholine receptor (nAChR) agonist that activates the trigeminal parasympathetic pathway and can be used to treat dry eye.

Navamepent (RX-10045) is an analog of resolvin E1 (a dietary-3 polyunsaturated fatty acid metabolite), which has potent anti-inflammatory activity that reduces corneal inflammation, epithelial damage, and accelerates corneal tissue repair.Navamepent inhibits the release of several key pro-inflammatory mediators from corneal epithelial cells.Navamepent is very effective against dry eye and cupping cell loss Navamepent is effective against dry eye and cupping cell loss, and accelerates tear production.

Gefarnate is a synthetic compound used for the treatment of gastric ulcers,and also used in the treatment of dry eye syndrome.

Reproxalap (NS-2) covalently binds aldehydes including malondialdehyde and 4-hydroxynonenal. Reproxalap is a reactive aldehyde species sequestering agent for the treatment of the dry eye.

Tavilermide (MIM-D3) is a selective TrkA agonist, a cyclic mimetic, which can be used to study dry keratoconjunctivitis and dry eye syndrome.

UAMC-00050 free base is an effective inhibitor of trypsin-like serine proteases. It is applicable in research related to dry eye syndrome and ocular inflammation.

GW559090 is a selective, competitive, and high-affinity α4 integrin antagonist with a Kd value of 0.19 nM for α4β1. It effectively inhibits the binding of α4β1 to vascular cell adhesion molecule 1 (VCAM-1) and fibronectin, with IC50 values of 7.72 and 8.04 nM, respectively. Additionally, GW559090 suppresses the interaction between α4β7 and mucosal addressin cell adhesion molecule 1 (MAdCAM-1) with an IC50 value of 23 nM. It also inhibits inflammatory infiltration in the eye, repairs the corneal barrier, and restores goblet cell function, making it useful for research into dry eye syndrome associated with Sjögren's syndrome.

LFA-1-IN-2 (Compound 25) is a potent LFA-1 inhibitor with a Kd value of 21.46 μM. It effectively inhibits ICAM-1-mediated cell adhesion. Additionally, LFA-1-IN-2 can protect cells from inflammatory hyperosmotic stress damage and improve dry eye conditions.

BI-1124 is a cathepsin S inhibitor that demonstrates simulated adequate ocular pharmacokinetic-pharmacodynamic coverage when administered topically in rabbit models. It is applicable for research on age-related dry eye syndrome.

R-932348 choline, a dual JAK/SYK inhibitor, is used potentially for treatment of dry eye disease.

Icomucret can be used for the Treatment of Dry Eye.

Lifitegrast sodium (SAR-1118-023 sodium) is a small molecule integrin antagonist that inhibits T cell-mediated inflammation by blocking the binding of two important cell surface proteins (lymphocyte function-associated antigen 1 and intercellular adhesion molecule 1), which reduces inflammation of the ocular surface, and may be used in the study of dry eye.

Nimucitinib is a Janus kinase (JAK) inhibitor that can be used to treat dry eye and promote tear production.

TOP1362 is a Narrow Spectrum Kinase Inhibitors Demonstrate Promise for the Treatment of Dry Eye Disease and Other Ocular Inflammatory Disorders. TOP1362 strongly inhibited the kinase targets p38α, Syk, Src, and Lck, blocked the rise in p38α expression in hyperosmolar Chang cells, and potently reduced inflammatory cytokine release in cellular models of innate and adaptive immunities. In the EIU model, TOP1362 dose-dependently attenuated the LPS-induced rise in inflammatory cell infiltration and ocular cytokine levels with efficacy comparable to that of dexamethasone.

Diquafosol Tetrasodium is a P2Y2 receptor agonist that stimulates the secretion of mucins from ocular tissues Diquafosol tetrasodium (INS365) improves tear film stability and visual function, as a topical treatment of dry eye disease.

Tanfanercept (HL036337), an anti-TNF-α monoclonal antibody, has shown efficacy in reducing corneal erosions in a dry eye (DE) mouse model [1] [2].

JAK-IN-30 (compound 31) is a water-soluble Janus kinase (JAK) inhibitor with IC50 values of 2 nM for JAK2, 15 nM for JAK1, 18 nM for JAK3, and 2 nM for TYK2, identified for its research potential in treating dry eye disease (DED) [1].

Vezocolmitide, a collagen-mimicking peptide, is a component of ST-100. It is applicable in the study of dry eye disease (DED).